{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"7.4","value":"4.8"},{"groupId":"OG002","lowerLimit":"8.5","upperLimit":"8.5","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Duration of response will be defined as the time from first objective status assessment of response to the time of first documented disease progression or death.","dispersionType":"Full Range","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5mg Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10 mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15mg Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"Duration of best response calculated only for participants who achieved a PR or better.","reportingStatus":"POSTED","timeFrame":"approx. 5 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}